Research
Hormonal
Semaglutide improved glycemic control, with HbA1c decreasing by 0.4 ± 0.6%.
Semaglutide may be a beneficial treatment for improving glycemic control in patients with type 1 diabetes.
StrongSupportsmedium confidence
HbA1c decreased by 0.4 ± 0.6% ( P < 0.001), with 42% achieving a reduction of ≥0.5%.
Why this rating
Based on the real-world study design with a significant sample size.
Source
Real-World Evidence of the Effect of Adjunctive Semaglutide on Weight Change, Glycemic Control, and Metabolic Dysfunction-Associated Steatotic Liver Disease in People with Type 1 Diabetes
Jonathan Mertens et al. · Diabetes Technology & Therapeutics · 2025
DOI 10.1177/15209156251362497
cohort · n=42Cited 3×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →